Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutics and Orna Therapeutics in the past year, each taking different approaches to developing in vivo genetic medicines.
Rachel Springate, general partner at Muse Capital, said the next wave of healthcare startups will be driven by consumer demand — but pure direct-to-consumer models rarely work. Companies like Midi Health, Mavida Health and Mahmee are showing a different path: starting with patients, collecting outcomes data, and integrating with clinicians, payers and the broader healthcare system.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Waiv, formerly the diagnostics division of AI biotech Owkin, developed AI-enabled testing technologies that found use in clinical settings and in cancer drug research. Spinning out as an independent company enables Waiv to pursue its own growth strategy, co-founder and CEO Meriem Sefta said.
Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.
Quibim’s technology applies artificial intelligence analysis to medical images to detect biomarkers. Hospitals and biopharma companies are among the startup’s customers, using its technology to analyze images to detect disease and guide clinical trial enrollment.
Being Health, a startup that launched last week, offers a care team that includes psychiatrists, psychotherapists, nurse anesthetists, functional medicine physicians, nutritionists, acupuncturists and care advocates. It serves patients both virtually and in person.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Malla, a startup that launched Wednesday, is trying to make functional, personalized medicine more accessible. Consumers can purchase a membership, which includes one-on-one video sessions with a practitioner, messaging, personalized care plans and tracking.
Override provides chronic pain patients with a care team that includes a pain physician, a physical therapist, a psychologist and a coach. The company has received $3.5 million in seed funding and has acquired Take Courage Coaching.
Though the Medicare Advantage-focused insurance technology startup is smaller than rivals like Clover Health in terms of membership and revenues, this latest financing round places it ahead of, or at least on par with, several larger competitors with regard to total funds raised.
Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Frank Westermann sold his previous startup, mySugr, to Roche four years ago. Now, he’s starting a new company with the goal of making healthcare providers and diabetes medications more accessible.
Anil Sethi was the director of health records at Apple until his sister was diagnosed with metastatic breast cancer, and given weeks to live. After traveling with her to different doctors across the country, and helping carry her records, Sethi created his own company to pull together harder-to-find records, such as scans and pathology reports.
Cigna Ventures and Blue Shield of California contributed to a funding round for Cricket Health, a startup that provides services to help patients identify chronic kidney disease and get support in treatment. The investment was led by Valtruis, a firm that invests in value-based care companies.
DrChrono, one of the first companies to build out a mobile-friendly EHR, raised $12 million in funding. The startup plans to use the funds to build out its telehealth platform.
Five Blue Cross Blue Shield plans provided funding to establish Evio, which aims to improve clinical outcomes and cut drug costs. It will initially only offer services to the founding health plans, including data analytics to determine drug performance and enhancing outcomes-based contracting.